Wolfe: 'Arrowhead Q3 data in acute pancreatitis will be the next big event to readthrough to Ionis. We see 74% odds of IONS stock down, 26% odds up'
Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)